Pharmacokinetics and Metabolism of Mitoxantrone A Review

Clinical Pharmacokinetics

Volumn 18, Issue 5, 1990, Pages 365-380

  Ehninger, Gerhard ^a   Schuler, Ulrich ^a   Proksch, Barbara ^a   Zeller, Klaus Peter ^a   Blanz, Joachim ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MITOXANTRONE; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; DOG; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER FAILURE; MASS SPECTROMETRY; MONKEY; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW;

ANIMAL; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMAN; INFUSIONS, INTRAVENOUS; LEUKEMIA; LIVER DISEASES; LYMPHOMA; MITOXANTRONE;

EID: 0025255167     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199018050-00003     Document Type: Article

References (109)

1. Pharmacology of mitoxanirone: mode of action and pharmacokinetics
2. Mechanism of action and pharmacokinetics of novamrone in intravenous and intraperiloncal therapy
3. Disposition of mitoxantrone in patients
4. Disposition of mitoxantrone in cancer patients
5. Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration
6. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations available by intraperitoneal administration
7. Pharmacokinetics of dihydroxyanthracenedione (DHAD) and its metabolites in rats. Abstract
8. Anthracycline antibiotic pharmacology and metabolism: the inhibitory effect of 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione dihydrochloride on dividing and nondividing cells in vitro. Abstract
9. Evidence for human liver mediated free-radical formation by doxorubicin and mitozantrone
10. Pharmacokinetics of mitoxantrone in man and laboratory animals
11. C-Markierung der Seitenketten von Mitoxantrone
12. Escalating dose regimen of intraperitoneal mitoxantrone: phasel study of intraperitoneal mitoxantrone — clinical and pharmacokinetic evaluation
13. Comparative molecular pharmacology in leukemia LI210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene
14. Membrane lipid alterations: effect on cellular uptake of mitoxantrone
15. Membrane transport of mitoxantrone by L1210 leukemia cells
16. A theoretical investigation on the sequence selective binding of mitoxantrone to doublestranded tetranucleotides
17. The collaborative development of a new family of antineoplastic drugs
18. Identification of human urinary mitoxantrone metabolites
19. Biliary pharmacokinetics of mitoxantrone in the rat following different intravenous doses and characteristics of drug related material in the bile. Abstract
20. Mitoxantrone in hepatic dysfunction: factors influencing toxicily and response. Abstract
21. High-performance liquid Chromatographie assay for mitoxantrone in plasma using electrochemical detection
22. Protein associated DNA single strand breaks and cytotoxicity of dihydroxyanthracenedione (DHAD) in mouse LI210 leukemia cells. Abstract
23. Mitoxantrone affects lopoisomerase activities in human breast cancer cells
24. Mitoxantrone determination using high-performance liquid chromatography: improved sensitivity by loop-column injection for dual-dose pharmacokinetic studies
25. Arterielle regionale Chemotherapie fortgeschrittener Mammakarzinome
26. Comparative cardiac oxygen radical production by anthracycline antibiotics, mitoxantrone, bisantrene. M-AMSA, and neocarzinostatin. Abstract
27. An overview of cardiac episodes following mitoxantrone administration
28. Molecular and biochemical pharmacology of mitoxantrone
29. Biologie and biochemical effects of mitoxantrone
30. In vitro and in vivo metabolism of mitoxantrone
31. Klinische Pharmakologie von Mitoxantron bei Patienten mit Mammakarzinom und Leukamien
32. Mitoxantrone metabolism in the isolated perfused rat liver
33. The pharmacokinctics and metabolism of mitoxantrone in man
34. Clinical pharmacology of mitoxanlrone
35. Detection and separation of mitoxantrone and its metabolites in plasma and urine by HPLC
36. Selective immunomodulatio by the antineoplastic agent mitoxantrone
37. Mitoxantrone inhibits helper function and enhances suppressor activity
38. Development of a sensitive monoclonal antibody-based-enzyme-linked immunosorbent assay (ELISA) for mitozantrone
39. DNA sequence preferences for the anticancer drug miloxamrone and related anthraquinones revealed by DNase I fool-printing
40. DNA-binding specificity and RNA Polymerase inhibitor activity of bis (aminoalkyl) anthraqumones and bis (methyl-thio) vinylquinonc Jodides
41. 2 production in vivo
42. Effects of mitoxantrone and bisantrene on platelet aggregation and prostaglandin/thromboxane biosynthesis in vitro
43. Warning against use of intrathecal mitoxantrone
44. Milozanlronc-induced toxicity and DNA strand breaks in leukaemic cells
45. Application of electrochemical detection for the quantitation of 1.4-dihydroxy-5.8-bis-[2-(2-hydroxyelhyl)amino-elhylamino]-9.10-anthracenedione following liquid chromatography
46. HPLC determination of mitoxantrone in biological fluids: a sensitive and accurate method
47. Plasma kinetics of mitoxantrone in leukemic patients
48. Preclinical toxicology studies on mitoxantrone and bisantrene
49. Experimental antilumour activity of aminoanthraquinones
50. Relationship between the pharmacological activit) of aniuumor drugs ametantronc and mitoxantrone (novantronc) and their ability to condense nucleic acids
51. Interactions of a new antitumour agent, 1,4-dihydroxy-5,8-bis [2-[(2-hydroxyethyl)amino]-ethyl]amino-9,10-anthracenedionc with nucleic acids
52. Inhibition of adriamycin stimulated microsomal lipid peroxidation by mitoxantrone and ametantrone, two new anthracencdione anlineoplastic agents
53. Mitoxantrone and ameiantronc inhibil hydropcroxide-dependent initiation and propagation reactions in fatty acid peroxidation
54. Paraplegia after intrathecal mitozantrone
55. Intrathecal mitozantrone
56. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia
57. High-performance liquid Chromatographie determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorpuve losses on glass during sample preparation
58. High field H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex (d(CpGpCpG)]
59. Interactions of the antitumor agents miloxamrone and bisantrene with deoxyribonucleic acids studied by electron microscopy
60. Characteristics of the binding of the anticancer agents mitoxantrone and ametamrone and related structures to deoxyribonucleic acids
61. Pharmacological disposition of 1,4-dihydroxy-5,8-bis [2-[(2-hydroxyethyl)amino]cthyl]amino-9, 10-anthracenedione dihvdrochloride in the dog
62. Pharmacokineties and metabolism of mitoxanlrone
63. Differential effects of anthracycline drugs on the rat heart and liver microsomal reduced niconnamidc adenine dinucleotide phosphate-dependent lipid peroxidation
64. High-dose cyclophosphamide or melphalan with escalating doses of miloxamrone and autologous bone marrow transplantation for refractory solid lumors
65. Antitumour Agents. 1. 1.4-Bis-[(aminoalkyl)amino]-9.10-anlhracenediones
66. Intrapleurale Applikation von Mitoxanlron zur Behandlung ausgedehnter Pleuraergusse bei metastasiertem Mamma-Ca
67. Radioimmunoassay for muoxantrone, a new antitumor agenl
68. Mitoxantrone: propensity for free radical formation and lipid peroxidation-implications for cardiotoxicity
69. Effects of cell density on druginduced cell kill kinetics in vitro (inoculum effect)
70. An HPLC method for the quantitative determination of 1.4-dihydro.xy-5.8-bis-[2-[2-hydroxyethyl)amino]ethyl]amino-9.10-anthracencdione in serum
71. Direct determination of miloxamrone and its mono- and dicarboxylic metabolites in plasma and urine by high-performance liquid Chromatography
72. Improved highperformance liquid Chromatograph) of the new antineoplastic agents bisantrene and mitoxamrone
73. Mitoxantrone extravasation injury
74. Clinical analysis for the antineoplastic agent l.4-dihydroxy-5,8.-bis[2-[(2-hydroxyethyl)amino)-ethyl]amino-9. 10-anthracenedione dihydrochloride in plasma
75. Excretion and metabolism of mitoxantrone in rabbits
76. Detection and quantification of mitoxantrone in human organs: a case report
77. Comparison of the interaction of antineoplastic aminoanthraquinones with DNA using competitive fluorescence polarization
78. Clinical kinetics of l.4-dihydroxy-5.8-bis-[2-hydroxyethyl)-aminojethyljaminol-9.10-anthracenedione
79. Pharmacology of mitoxantrone in cancer patients
80. Clinical kinetics of l.4-dihydroxy-5.8-bis-[2-[(2-hydroxyethyl)amino]ethyl]-amino)-9,10-anthracenedione
81. Therapeutic activity of mitoxantrone and ametantrone against murine tumors
82. Potential cardiotoxicity with mitoxantrone
83. Mitoxantrone — an immunosuppressive agent potentially useful in the organ transplantation. Abstract
84. Mitoxantrone: a new anlicancer drug with significant clinical activity
85. Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma
86. Early and delayed neurotoxicity of mitoxantrone and doxorubicin following subarachnoid injection
87. The clinical pharmacology of mitoxantrone
88. Human autopsy tissue concentrations of mitoxantrone
89. Clinical and clinical pharmacologic studies of mitoxantrone
90. Cardiotoxicity associated with mitoxantrone
91. Effect of 1,4-dihydroxy-5.8-bis-[2-[(2-hydroxyethyl)amino-ethyl]amino-9.10-anthracenedione (dihydroxyamhraquinone) on the replication of simian virus 40 chromosome
92. High-performance liquid chromatography of cancer chemotherapeutic agents: bis(substituted aminoalkylamino)anthraquinones
93. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
94. Brain tissue concentrations of mitoxantrone in the rat brain after iv and ia administration
95. Histologie and functional characteristics of human heart after mitoxantrone therapy
96. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy
97. Ion-paired high-performance liquid Chromatographie determination of mitoxantrone in physiological fluids
98. Development of resistance and characteristics of a human colon carcinoma sublinc resistant to mitoxantrone in vitro
99. Inhibition of the induction of alloreactivity with mitoxantrone
100. Relationship of chemical structures of anthraquinones with their effects on the suppression of immune responses
101. Evidence for the metabolism of mitoxantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases
102. Structure-activity relationship study of anthraquinones: 1.4-dihydroxy-5,8-bis-[2-[(hydroxyethoxy)-ethyl]amin-9.10-anthracenedione, an analog of an established antineoplastic agent
103. Anthraquinone anticanccr agents
104. Intrathecal mitozantrone for resistant leukaemia